AGTC 
Welcome,         Profile    Billing    Logout  
 7 Products   10 Diseases  7 Products   7 Trials   120 News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rAAV2tYF-CB-hRS1 / AGTC
NCT02416622: Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

Checkmark Efficacy data in patients with X-linked Retinoschisis
Dec 2018 - Dec 2018: Efficacy data in patients with X-linked Retinoschisis
Checkmark Data on the dose escalation phase for X-linked retinoschisis
Jun 2017 - Jun 2017: Data on the dose escalation phase for X-linked retinoschisis
Checkmark Data on the dose escalation phase for X-linked retinoschisis
More
Completed
1/2
27
US
rAAV2tYF-CB-hRS1
Applied Genetic Technologies Corp
X-linked Retinoschisis
04/19
05/23
NCT02317887: Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

Completed
1/2
12
US
RS1 AAV Vector
VegaVect, Inc., National Eye Institute (NEI)
Retinoschisis, X-Linked
04/24
10/24
NCT06066008: Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients

Recruiting
1
9
RoW
ZM-01-L, rAAV-hRS1, ZM-01-H
Zhongmou Therapeutics
X-linked Retinoschisis
10/23
10/27
rAAV2-CB-hRPE65 / AGTC
NCT04731883: RPE65 Gene Therapy （LX101）for Leber's Congenital Amaurosis

Not yet recruiting
N/A
9
RoW
Gene therapy-LX1010(AAV2-RPE65), Gene treatment arm
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Leber Congenital Amaurosis
12/22
06/23
NCT06024057: An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Not yet recruiting
N/A
3
NA
LX101
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
09/28
09/38
laruparetigene zovaparvovec (AGTC-501) / AGTC
NCT04850118: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Recruiting
2/3
75
Europe, US, RoW
rAAV2tYF-GRK1-hRPGRco, AGTC-501, Control, Untreated Control Group
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
08/25
10/29
NCT06333249: A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Active, not recruiting
2
14
US
rAAV2tYF-GRK1-RPGR
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
04/23
02/27
AGTC-RPGR-001, NCT06275620: A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Enrolling by invitation
2
24
US
AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
11/25
12/29
HORIZON, NCT03316560: Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

Active, not recruiting
1/2
29
US
rAAV2tYF-GRK1-RPGR
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
11/23
03/25
AGTC-402 / AGTC
NCT02935517: Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

Active, not recruiting
1/2
24
US, RoW
AGTC-402, rAAV2tYF-PR1.7-hCNGA3
Applied Genetic Technologies Corp
Achromatopsia
08/22
08/26
BS01 / Bionic Sight, AGTC
NCT04278131: BS01 in Patients With Retinitis Pigmentosa

Recruiting
1/2
20
US
BS01
Bionic Sight LLC
Retinitis Pigmentosa
12/24
12/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rAAV2tYF-CB-hRS1 / AGTC
NCT02416622: Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

Checkmark Efficacy data in patients with X-linked Retinoschisis
Dec 2018 - Dec 2018: Efficacy data in patients with X-linked Retinoschisis
Checkmark Data on the dose escalation phase for X-linked retinoschisis
Jun 2017 - Jun 2017: Data on the dose escalation phase for X-linked retinoschisis
Checkmark Data on the dose escalation phase for X-linked retinoschisis
More
Completed
1/2
27
US
rAAV2tYF-CB-hRS1
Applied Genetic Technologies Corp
X-linked Retinoschisis
04/19
05/23
NCT02317887: Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

Completed
1/2
12
US
RS1 AAV Vector
VegaVect, Inc., National Eye Institute (NEI)
Retinoschisis, X-Linked
04/24
10/24
NCT06066008: Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients

Recruiting
1
9
RoW
ZM-01-L, rAAV-hRS1, ZM-01-H
Zhongmou Therapeutics
X-linked Retinoschisis
10/23
10/27
rAAV2-CB-hRPE65 / AGTC
NCT04731883: RPE65 Gene Therapy （LX101）for Leber's Congenital Amaurosis

Not yet recruiting
N/A
9
RoW
Gene therapy-LX1010(AAV2-RPE65), Gene treatment arm
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Leber Congenital Amaurosis
12/22
06/23
NCT06024057: An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Not yet recruiting
N/A
3
NA
LX101
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
09/28
09/38
laruparetigene zovaparvovec (AGTC-501) / AGTC
NCT04850118: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Recruiting
2/3
75
Europe, US, RoW
rAAV2tYF-GRK1-hRPGRco, AGTC-501, Control, Untreated Control Group
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
08/25
10/29
NCT06333249: A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Active, not recruiting
2
14
US
rAAV2tYF-GRK1-RPGR
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
04/23
02/27
AGTC-RPGR-001, NCT06275620: A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Enrolling by invitation
2
24
US
AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
11/25
12/29
HORIZON, NCT03316560: Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

Active, not recruiting
1/2
29
US
rAAV2tYF-GRK1-RPGR
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
11/23
03/25
AGTC-402 / AGTC
NCT02935517: Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

Active, not recruiting
1/2
24
US, RoW
AGTC-402, rAAV2tYF-PR1.7-hCNGA3
Applied Genetic Technologies Corp
Achromatopsia
08/22
08/26
BS01 / Bionic Sight, AGTC
NCT04278131: BS01 in Patients With Retinitis Pigmentosa

Recruiting
1/2
20
US
BS01
Bionic Sight LLC
Retinitis Pigmentosa
12/24
12/29

Download Options